Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
about
Voriconazole therapeutic drug monitoring.Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicansMelanized fungi in human diseaseFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalAdvances in the treatment of invasive neonatal candidiasisPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsEpidemiology of invasive candidiasis: a persistent public health problemSimultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography.Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.Antifungal and antiviral agents: a review.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.The past, present and future of antimycotic combination therapy.Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.Antifungal susceptibility testing: practical aspects and current challenges.In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Antifungal pharmacodynamics: review of the literature and clinical applications.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Primary central nervous system phaeohyphomycosis: a review of 101 cases.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Rationale for combination antifungal therapy.Systemic antifungal agents.Antifungal agents: chemotherapeutic targets and immunologic strategies.Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Has antifungal susceptibility testing come of age?In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectEfficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis.In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in CambodiaNovel strategies to fight Candida species infection.Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.Antifungal pharmacokinetics and pharmacodynamicsOptimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingCombination Antifungal Therapy: A Review of Current Data.Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory.Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Antifungal therapeutic drug monitoring: established and emerging indications.
P2860
Q24542411-AD1F9FA5-CF57-4CCB-BC54-F21DE0A25351Q24550731-ACB1BA66-3E10-45EA-B995-0B8F9D1BDC6DQ24633163-70CF28B2-704A-4318-A9F0-F7F4E2C5EAF0Q27012487-B96E03B1-FD12-49FF-A0D5-7B68BFEAF1C6Q27022585-AEC19328-F3C9-4F83-B5BD-EEBE7FA57F0FQ27025299-078412E8-1EB7-4562-A1B3-293AE21DDD31Q29616758-F23CB6B9-C905-4293-94A4-F4E632F45C5DQ30984298-9AB42329-024B-40F4-8621-D8A922DB313BQ33200348-60EB5359-231F-46A2-8875-2F0F2EFE1225Q33341541-7FF69364-1ED5-4D57-BCDE-E5E6BA995D40Q33539956-08DF8C59-853D-4BA0-80E2-A6EA3141BC4DQ33721804-8B53F935-29B7-4A11-89F5-42C939958E95Q33760507-25DC8281-A08D-4E2F-8F62-2D5DA1C1C0AEQ33894467-F9C6F02F-4C6D-4DBC-818E-8B431E057005Q33975757-01E665B1-D812-4189-AC61-A905CA54E949Q33979115-47869C7D-82F1-40B5-9899-BDD6D0B16F46Q34083129-D1465BAF-22CA-4B88-B140-03A530E24511Q34108880-F15ED66F-C9C2-400B-938B-293308ECE969Q34142406-73E4244C-BC94-46FE-BA29-21CA906CE2A4Q34286912-CA18EB44-818C-4533-9699-1BE51A556314Q34335230-4501CB37-28D1-4BDF-8B1B-53D34013046DQ34335236-764AE12D-D10B-4F5C-855C-7BF8E6420304Q34344425-6D73A33E-2A7E-434F-8296-CBC97C00B13FQ34400044-63714B3A-2527-47F5-AEDD-D8D070E00D8DQ34459194-FCC56C36-0268-43AD-AFC9-76718B8305CBQ34505582-DBF5410D-AF87-4F81-9A20-F0A413F46B0AQ34923038-A2350593-F23D-44D9-A1E0-F813AE83D7CAQ35091285-F0D24F7C-7636-4863-844D-07B9A541A09DQ35127913-49B4F620-753A-4869-8C69-25EFC7F2EB84Q35130582-88E3ED02-EE05-4AB3-A761-552B42FE9FFCQ35220825-C4FAC8B8-CF40-4E38-9751-5DB9E2F1C0DFQ35406737-26384F48-B96A-4346-AFF0-39168BDBE1B0Q35647796-FB7BDD9F-C9FA-4322-AE52-CA309E2B658CQ35663841-A39B311C-F699-4215-BCF0-40701F759EC4Q36094962-5E98645B-ACAE-4B51-A06A-0F61FB5E089BQ36369805-A22A23C2-3F1E-4E46-8C72-CA851FAD4995Q36523393-7996708B-5E68-4129-B85A-2758A99F80F2Q36534003-D1814F52-8729-46F3-8F83-C29D86BF0266Q37157893-9B0F9E64-064A-404B-A7AB-DEC12ACF50E4Q37310029-46B84D60-BFC5-4D7C-885D-98137CC4A7C9
P2860
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
description
1992 nî lūn-bûn
@nan
1992 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
name
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@ast
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@en
type
label
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@ast
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@en
prefLabel
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@ast
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@en
P356
P1476
Evolving role of flucytosine i ...... etics, and antifungal therapy.
@en
P2093
P304
P356
10.1093/CLIND/15.6.1003
P407
P577
1992-12-01T00:00:00Z